Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling to Successfully Develop Stable, Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation into the Clinic
Welcome to the 7th RNA Targeted Drug Discovery & Development Summit: Accelerating Safe & Potent RNA-Targeting Small Molecules Towards the Clinic
With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins and RNA/protein complexes.
Hence, as the go-to meeting for the RNA-targeting small molecule the community, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures, delve into innovative preclinical modelling strategies and identify optimal chemical features for advancing specific, efficacious and safe small molecules.
Unite with 100+ RNA Science, Medicinal Chemistry, Structural Biology & Biophysics experts from the likes of AstraZeneca, Sanofi, Novartis, PTC Therapeutics, ReviR Therapeutics, Rgenta Therapeutics, Accent Therapeutics and more at the most comprehensive and definitive event for the community, the 7th RNA-Targeted Drug Discovery & Development Summit, to accomplish faster and smoother translation of RNA targeted therapies towards the clinic.
Attendee Snapshot:
What's New for 2024?
Increased Content on Preclinical Work & Translation – The 2024 Focus Day will offer a unique opportunity to deep-dive into novel strategies for translation, as we spend the entire day delving into innovative preclinical models testing, identifying more reliable safety strategies to accelerate safer and more effective therapeutics into the clinic.
Fresh Insights & Brand-New Data – With 80% of the Speaker Faculty being brand-new, including new companies and organizations such as AstraZeneca, Sanofi, Genetic Leap, UNC at Chapel Hill and more, access the latest strategies in RNA target discovery and optimizing small molecule selectivity.
New Content on Investment & Collaboration – During an interactive fireside chat, investment and business development leaders from Abingworth, Accent Therapeutics and Base4 Biotechnology will join forces to discuss the newest trends in investment and funding for the RNA-targeting field.
2024 Expert Speakers Include:
2024 Partners Include:
Alisha Jones
Assistant Professor, Chemistry
New York University
Participating in the 7th RNA Targeted Drug Discovery and Development Summit presents an invaluable opportunity to network with industry leaders and gain insights into cutting-edge approaches and systems. I believe this meeting will inspire new ideas and methodologies that I can bring back to my lab, further advancing our research in RNA therapeutics
